personalized, responsive service and to improve the site, we remember and store information about how you use
Congratulations! You now have unlimited access to all articles from The Medicine Maker.
Complete your profile at your earliest convenience to unlock the rest of your benefits:
relevant and personalised updates about your field
access to White Papers/product profiles
digital magazine subscription
The Medicine Maker
The July/August issues features a celebration of philanthropy in the pharma industry, showcasing projects at a number of companies including GlaxoSmithKline and Morningside Pharmaceuticals. Upfront investigates Eli Lilly’s advances in continuous manufacturing and the perils of a “Bad Brexit”, and in In My View, Catherine Bollard argues that scientific funding cuts in the US could be detrimental to global health. In NextGen, Stephanie Corgie gives the story of Zymtronix and its enzyme immobilization technology; and in Best Practice, Stephen Tindal and Ronak Savla argue why a fresh approach to formulation for each new molecule is the most effective. We also Sit Down With Steve Davis, President and CEO of PATH.